On Mar. 23, 2020, Drug Innovation Ventures at Emory (DRIVE), and Ridgeback Biotherapeutics announced a collaboration to rapidly advance DRIVE’s EIDD-2801, a promising oral COVID-19 treatment, into human testing.

DRIVE is a not-for-profit biotechnology company wholly owned by Emory University, and Ridgeback is a closely-held biotechnology company based in Miami.